why did the fda ban tirzepatide on Compounded GLP-1 Drugs: What to Know FDA Warns on Certain Forms

The British Menopause Society has highlighted this concern, noting that while there is currently no robust data showing that GLP-1 receptor agonists definitively affect oral progestogen dosing requirements, bleeding patterns, or endometrial risk, the theoretical concern is valid and warrants monitoring

GSTC D gene at 4q24 location was identified as one of the primary genes that determine lung function [61]

This is because the dose of the medication needs to be slowly increased to the full dose over the first 9-16 weeks

Garca Rodrguez A, de la Casa M, Johnston S et al (2019) Association of polymorphisms in genes coding for antioxidant enzymes and human male infertility